

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/140427 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 17/00 (2006.01)
A61P 1/00 (2006.01) A61P 17/06 (2006.01)
A61P 1/06 (2006.01) A61P 17/14 (2006.01)
A61P 3/10 (2006.01) A61P 19/02 (2006.01)
A61P 11/06 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/IB2021/050013

(22) International Filing Date:

04 January 2021 (04.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/957,925 07 January 2020 (07.01.2020) US
63/116,120 19 November 2020 (19.11.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **LI, Meng**; c/o Pfizer Inc., 10777 Science Center
Drive, San Diego, California 92121 (US). **TOLCHER, An-
thony William**; c/o Next Oncology, 2829 Babcock Road,
Suite 300, San Antonio, Texas 78229 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd
Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRMT5 INHIBITOR FOR USE IN A METHOD OF TREATING PSORIASIS AND OTHER AUTOIMMUNE
CONDITIONS

(57) Abstract: Use of PRMT5 inhibitors such as and includ-
ing (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-
methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol: (I) or a pharmaceutically accept-
able salt thereof, to treat psoriasis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA),
psoriatic arthritis and other autoimmune conditions or disorders.

FIG. 1A






FIG. 1B



(I)



WO 2021/140427 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*